抗HCV小分子化合物的研究
The current standard treatment for hepatitis C virus (HCV) infection is a combination of pegylated interferon (PEG-IFN) and ribavirin. However, it remains incurable in some patients. In recent years, direct acting antiviral agents (DAAs) that target specific HCV enzymes in HCV life cycle have been d...
Main Author: | LI Minran |
---|---|
Format: | Article |
Language: | zho |
Published: |
Editorial Department of Journal of Clinical Hepatology
2014-06-01
|
Series: | Linchuang Gandanbing Zazhi |
Subjects: | |
Online Access: | http://www.lcgdbzz.org/qk_content.asp?id=5809&ClassID=42414946 |
Similar Items
-
直接抗病毒药物时代下对丙型肝炎研究的挑战
by: ZHONG Jin
Published: (2014-06-01) -
难治性丙型肝炎再认识—谈丙型肝炎抗病毒治疗策略的进展
by: DOU Xiaoguang
Published: (2014-06-01) -
Research progress in anti-HCV therapeutic regimens without interferon
by: LI Qiang, et al.
Published: (2016-01-01) -
Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure–Activity Relationships
by: Hu K, et al.
Published: (2020-02-01) -
Recent advances in the anti-HCV mechanisms of interferon
by: Menghao Huang, et al.
Published: (2014-08-01)